Name change for Epistem as it raises £6.5m

MANCHESTER biotech company Epistem Holdings has raised £6.5m through a share placing, to broaden the portfolio of its Genedrive tests, developed to fight infectious diseases such as TB across the globe.

The new ordinary shares will represent 43.5% of the company's enlarged share capital.

Cornerstone investor Calculus Capital subscribed for 3,125,000 placing shares, investing £2.5m of the total £6.5m raised and will hold 16.7% of the enlarged share capital.

The listed company has also announced ... You can carry on reading for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...